Clinical trials · California
Myeloproliferative Neoplasm clinical trials in California
We’re tracking 15 recruiting myeloproliferative neoplasm studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT07441694RecruitingPhase 1
Study of INCA036978 for blood cancers
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
Irvine, CaliforniaAges 18 years+ - NCT07008118RecruitingPhase 1
Study of INCA035784 for certain blood cancers
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT05123365RecruitingPhase 1/Phase 2
Testing a dose of N-acetylcysteine for certain blood cancers
This Phase 1/2 study tests what dose of N-acetylcysteine (NAC) is safe and potentially helpful for people with essential thrombocythemia, polycythemia vera, or myelofibrosis. It focuses on people who still have symptoms and meet blood and health requirements so researchers can monitor side effects and symptom changes.
Irvine, CaliforniaAges 18 years+ - NCT06034002RecruitingPhase 1
Study of INCA033989 for myeloproliferative neoplasms
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Downey, CaliforniaAges Up to 25 years - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Duarte, CaliforniaAges Any age - NCT06150157RecruitingPhase 1
Study of JNJ-88549968 for CALR-mutated blood cancers
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
Duarte, CaliforniaAges 18 years+ - NCT06059391RecruitingPhase 2
Vaccine for stem cell donors to prevent CMV
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Duarte, CaliforniaAges 18–75 - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT03779854RecruitingPhase 2
Preventing graft-versus-host disease in kids after stem cell transplant
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Los Angeles, CaliforniaAges 6 months–26 years - NCT04064060RecruitingPhase 3
Long-term safety follow-up for luspatercept study participants
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
Los Angeles, CaliforniaAges 18 years+ - NCT06063486RecruitingPhase 2
Curcumin for inflammation and symptoms in blood disorders
This trial tests whether curcumin, a natural compound found in turmeric, can reduce inflammation and improve symptoms like fatigue in people with certain blood disorders that cause low blood counts or overproduction of blood cells. It is for patients with clonal cytopenia of uncertain significance, low-risk myelodysplastic syndrome, or myeloproliferative neoplasms (polycythemia vera, essential thrombocytosis, or myelofibrosis) who have bothersome symptoms.
Los Angeles, CaliforniaAges 18 years+ - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80 - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Palo Alto, CaliforniaAges 18–66
Myeloproliferative Neoplasm trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting myeloproliferative neoplasm studies listed above.
- City of Hope Comprehensive Cancer Center · 7 studies
- Children's Hospital Los Angeles · 2 studies
- Stanford University · 2 studies
- University of California Davis Comprehensive Cancer Center · 2 studies
- University of California, Irvine Medical Center / UC Irvine Health · 2 studies
- University of California, Los Angeles (UCLA) · 2 studies
- USC / Norris Comprehensive Cancer Center · 2 studies
- Cedars-Sinai Medical Center
What taking part in a myeloproliferative neoplasm study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Myeloproliferative Neoplasm trials in other states
Common questions
- Are there myeloproliferative neoplasm clinical trials in California?
- Yes. We're currently tracking 15 recruiting myeloproliferative neoplasm studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a myeloproliferative neoplasm study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a myeloproliferative neoplasm trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New myeloproliferative neoplasm studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.